GSK plc (NYSE:GSK) Shares Sold by Hall Laurie J Trustee

Hall Laurie J Trustee cut its stake in GSK plc (NYSE:GSK) by 24.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,075 shares of the pharmaceutical company’s stock after selling 346 shares during the quarter. Hall Laurie J Trustee’s holdings in GSK were worth $37,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of GSK. Eastern Bank acquired a new stake in shares of GSK in the third quarter worth approximately $26,000. ST Germain D J Co. Inc. boosted its stake in GSK by 195.5% during the 4th quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company’s stock worth $27,000 after purchasing an additional 522 shares during the last quarter. Sunbelt Securities Inc. grew its holdings in shares of GSK by 73.8% during the third quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock worth $29,000 after buying an additional 302 shares in the last quarter. Concord Wealth Partners raised its position in shares of GSK by 231.8% in the third quarter. Concord Wealth Partners now owns 783 shares of the pharmaceutical company’s stock valued at $32,000 after buying an additional 547 shares during the last quarter. Finally, Fortitude Family Office LLC purchased a new position in shares of GSK in the third quarter worth about $42,000. 15.74% of the stock is currently owned by hedge funds and other institutional investors.

GSK Trading Up 0.0 %

Shares of GSK stock opened at $33.46 on Monday. GSK plc has a fifty-two week low of $31.72 and a fifty-two week high of $45.92. The company has a debt-to-equity ratio of 0.98, a quick ratio of 0.53 and a current ratio of 0.81. The firm has a market capitalization of $69.34 billion, a price-to-earnings ratio of 21.72, a PEG ratio of 1.44 and a beta of 0.63. The stock has a 50 day moving average of $34.02 and a 200 day moving average of $37.98.

GSK Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, January 9th. Investors of record on Friday, November 15th were given a dividend of $0.3928 per share. This represents a $1.57 dividend on an annualized basis and a dividend yield of 4.70%. This is an increase from GSK’s previous quarterly dividend of $0.38. The ex-dividend date was Friday, November 15th. GSK’s dividend payout ratio (DPR) is presently 96.10%.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the stock. Jefferies Financial Group cut shares of GSK from a “buy” rating to a “hold” rating and dropped their price objective for the company from $53.00 to $39.50 in a research note on Tuesday, November 12th. Deutsche Bank Aktiengesellschaft lowered GSK from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. StockNews.com upgraded GSK from a “buy” rating to a “strong-buy” rating in a research report on Monday, January 13th. Finally, Guggenheim cut GSK from a “buy” rating to a “neutral” rating in a report on Thursday, October 31st. Seven equities research analysts have rated the stock with a hold rating and four have issued a strong buy rating to the stock. According to MarketBeat.com, GSK presently has a consensus rating of “Moderate Buy” and an average target price of $43.25.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.